ArticleJournal of advanced research2026
S100B induces angiogenesis via the clathrin/FOXO1/β-catenin signaling pathway and contributes to Bevacizumab resistance in epithelial ovarian cancer.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ginsenoside Rh7 ameliorates myocardial injury in diabetic cardiomyopathy by promoting M2 polarization of macrophages via SIRT1/FOXO1/β-catenin.Journal of ginseng research · 2026Article
- S100B drives glioblastoma invasion and migration through TGF‑β2‑mediated epithelial‑mesenchymal transition.Oncology reports · 2026Article
- Targeted protein degradation of Wnt/β-catenin signaling pathway: an effective strategy for cancer therapy.Journal of translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBevacizumab (BEV), the most common antiangiogenic agent for treating ovarian cancer, prolongs progression-free survival (PFS) but does not significantly improve overall survival (OS). Improving the limited clinical benefit of BEV remains a major challenge in ovarian cancer treatment. Although several studies have explored the mechanisms underlying tumor resistance to BEV, the clinical translation of these findings to overcome BEV resistance has been limited.
objectivesTo identify the key molecules and mechanisms that modulate ovarian cancer sensitivity to BEV.
methodsRNA sequencing was conducted on BEV-sensitive and BEV-resistant mouse ovarian cancer tissue to identify differentially expressed genes (DEGs). A prognostic assessment was performed and a risk signature was constructed using these DEGs and the BEV-related sequencing datasets. S100B was identified and assessed in angiogenesis using tube formation, 3D fibrin bead sprouting, wound healing, and migration assays. Downstream targets and signaling pathways of S100B in HUVECs were identified by proteomics and validated by western blot. The effect of S100B inhibitors on BEV efficacy was evaluated using in vivo experiments.
resultsA BEV-related prognostic signature comprising 11 genes was constructed. Of these, S100B expression significantly increased in BEV-resistant mouse ovarian cancer tissue and significantly correlated with poor PFS and OS of ovarian cancer patients treated with a BEV combination chemotherapy. HUVECs co-cultured with S100B-overexpressing ovarian cancer cells promoted tube formation, sprouting, and migration. Exogenous S100B entered HUVECs via clathrin-mediated endocytosis, downregulated FOXO1 expression, and promoted β-catenin nuclear translocation and transcriptional activity, ultimately enhancing tube formation. The S100B inhibitor pentamidine significantly increased BEV responsiveness and prolonged survival in ovarian tumor-bearing mice.
conclusionS100B is a key molecule regulating ovarian cancer sensitivity to BEV. Paracrine S100B secreted by ovarian cancer cells acts on HUVECs, promoting angiogenesis through the FOXO1/β-catenin pathway. Pentamidine combined with BEV holds potential for overcoming BEV resistance in clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.